[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336861-105":59,"doc-detail-336861-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrative-multiomic-profiling-of-triple-negative-breast-cancer-for-identifying-suitable-therapies","Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies","","Triple-negative breast cancer (TNBC) is highly heterogeneous and lacks well-defined genomic, transcriptomic, or protein biomarkers that reliably map to specific targeted therapies. A multimodal study profiled a cohort of 95 TNBC cases, integrating tumor-infiltrating lymphocyte quantification by H&E, protein abundance assessment via IHC, NanoString BC360 transcriptomics, targeted DNA sequencing, and overall survival associations. Results linked RB1 mRNA/protein levels to RB functionality, defined transcriptomic clustering patterns, and characterized PDL1-positive and HER2-low subgroups. The dataset supports identifying biomarker interplay to guide suitable TNBC therapy selection.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrative-multiomic-profiling-of-triple-negative-breast-cancer-for-identifying-suitable-therapies/336861/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrative-multiomic-profiling-of-triple-negative-breast-cancer-for-identifying-suitable-therapies/336861.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What challenge in triple-negative breast cancer motivated this study?","Question",{"text":112,"@type":113},"The study addresses TNBC’s high heterogeneity and the limited understanding of how genomic, transcriptomic, and protein biomarkers correlate for guiding therapy selection.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What methods were used for the multimodal profiling?",{"text":117,"@type":113},"Tumor-infiltrating lymphocytes were quantified using H&E staining; protein levels were assessed by IHC; transcriptomics were measured using NanoString BC360; targeted DNA sequencing was performed on a subset; and associations with overall survival were evaluated.",{"name":119,"@type":110,"acceptedAnswer":120},"Which findings relate biomarkers to TNBC therapy suitability?",{"text":121,"@type":113},"RB1 mRNA and RB proteins correlated better with markers of retinoblastoma functionality than RB1 mutational status, and PAM50 classification showed survival differences, informing biomarker utility for identifying suitable TNBC therapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336861,1790864859,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies  \nBojana Jovanovi1,2,3, Sarah E. Church4, Kara M. Gorman4, Khrystyna North4, Edward T. Richardson III3,5, Molly DiLullo1,2, Victoria Attaya1,2, Julie Kasparian1,2, Ayesha Mohammed-Abreu1,2, Gregory Kirkner1,2, Melissa E. Hughes1,2, Nancy U. Lin1,2,3,  \nElizabeth A. Mittendorf2,3,6, Stuart J. Schnitt1,3,5, Sara M. Tolaney1,2,3, and Shom Goel1,2,3,7,8  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease that carries the poorest prognosis of all breast cancers. Although novel TNBC therapies in development are frequently targeted toward tumors carrying a specific genomic, transcriptomic, or protein biomarker, it is poorly understood how these biomarkers are correlated.\u003Cbr>Experimental Design: To better understand the molecular features of TNBC and their correlation with one another, we performed multimodal profiling on a cohort of 95 TNBC. Our approach involved quantifying tumor-infiltrating lymphocytes through hematoxylin and eosin staining, assessing the abundance of retinoblastoma, androgen receptor, and PDL1 proteins through IHC, and carrying out transcriptomic profiling using the NanoString BC360 platform, targeted DNA sequencing on a subset of cases, as well as evaluating associations with overall survival.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: Levels of RB1 mRNA and RB proteins are better correlated with markers of retinoblastoma functionality than RB1 mutational status. Luminal androgen receptor tumors clustered into two groups with transcriptomes that cluster with either basal or mesenchymal tumors. Tumors classified as PDL1-positive by the presence of immune or tumor cells showed similar biological characteristics. HER2-low TNBC showed no distinct biological phenotype when compared with HER2-zero. The majority of TNBC were classified as basal or HER2-enriched by PAM50, the latter showing significantly improved overall survival.\u003Cbr>Conclusions: Our study contributes new insights into biomarker utility for identifying suitable TNBC therapies and the intercorrelations between genomic, transcriptomic, protein, and cellular biomarkers. Additionally, our rich data resource can be used by other researchers to explore the interplay between DNA, RNA, and protein biomarkers in TNBC. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nTriple-negative breast cancer (TNBC) is a highly heterogeneous disease characterized by the absence of estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors (1, 2) and an increased likelihood of distant metastasis and death compared with other subtypes of breast cancer (3) . Treatment of  \n1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2Breast Oncology Program, Dana-Farber Brigham ","cbCaigJ7hDnyfdJ7","https://ap.wps.com/l/cbCaigJ7hDnyfdJ7","pdf",3925936,12,"English","# Purpose\n# Experimental Design\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What challenge in triple-negative breast cancer motivated this study?\",\"answer\":\"The study addresses TNBC’s high heterogeneity and the limited understanding of how genomic, transcriptomic, and protein biomarkers correlate for guiding therapy selection.\"},{\"question\":\"What methods were used for the multimodal profiling?\",\"answer\":\"Tumor-infiltrating lymphocytes were quantified using H\\u0026E staining; protein levels were assessed by IHC; transcriptomics were measured using NanoString BC360; targeted DNA sequencing was performed on a subset; and associations with overall survival were evaluated.\"},{\"question\":\"Which findings relate biomarkers to TNBC therapy suitability?\",\"answer\":\"RB1 mRNA and RB proteins correlated better with markers of retinoblastoma functionality than RB1 mutational status, and PAM50 classification showed survival differences, informing biomarker utility for identifying suitable TNBC therapies.\"}]","Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies | PDF",1790016892,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29a03a38f4701d49be7ee9cb22020d8f.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67fc04164726d86b2726a922090d24a4.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12b0e697f9b4882656fc98da9d4724bf.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a8d46fd6c976157a410d71c65afd290.webp",980,1311]